​B.S. in Biochemistry from Louisiana State University in 1982​​Ph.D. in Biochemistry from Louisiana State University in 1987Post-Doc ​Baylor College of Medicine, Houston, TX/NIH/Dept. of Cell Biology from 1987-91
Image of a computer simulation of a heart

"Our research has impact in: 1) uncovering disease mechanisms, 2) evaluating novel therapies, and 3) developing new imaging methods for diagnostics."

Brent A. French, Ph.D., Professor of Biomedical Engineering

Brent A. French combines advanced methods of targeted drug and gene delivery with biomedical imaging in vivo to explore novel targets and treatment strategies in cardiovascular disease and cancer.  Research interests of the Molecular Bioengineering Lab focus on developing new, more effective strategies for treating and preventing human disease. In parallel, we develop novel diagnostic imaging methods to better understand the progression/regression of disease and the impact of novel therapies on specific disease targets. A highly-collaborative, interdisciplinary approach is used to integrate recent technical advances in multiple fields with our highly translational research. In particular, cutting-edge imaging techniques such as MRI, PET and ultrasound are used to expedite research by providing accurate measures of novel therapies against cardiovascular disease and cancer.

Research Interests

  • Medical and Molecular Imaging
  • Cell and Molecular Biomechanics
  • Targeted Drug and Gene Delivery
  • Cardiovascular Disease

In the News

Selected Publications

  • Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction. J Control Release. 28(220 Pt A):556-67, 2015. Dasa SS, Suzuki R, Gutknecht M, Brinton LT, Tian Y, Michaelsson E, Lindfors L, Klibanov AL, French BA, Kelly KA.
  • Splenic leukocytes mediate the hyperglycemic exacerbation of myocardial infarct size in mice. Basic Res Cardiol. 110(4):39-54, 2015. Tian Y, French BA, Kron IL, Yang Z.
  • Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery. Gene Therapy 20(9):930-938, 2013. Katwal AB, Konkalmatt PR, Piras BA, Hazarika S, Li SS, Lye RJ, Sanders JM, Ferrante EA, Yan Z, Annex BH and French BA.
  • Robust cardiomyocyte-specific gene expression following systemic injection of AAV: In vivo gene delivery follows a Poisson distribution. Gene Therapy 18(1):43-52, 2011. Prasad K.M.R., Xu Y., Yang Z., Acton S.T., French B.A.

Courses Taught

  • BME 3080 - Biomedical Engineering IDEAS Laboratory
  • BME 4806 - Biomedical Applications of Genetic Engineering
  • BME 7806 - Biomedical Applications of Genetic Engineering

Featured Grants & Projects

  • Multi-parameter CMR of post-MI Left Ventricular Remodeling in Gene Modified Mice

    Source: NIH, NHLBI; R01 HL115225 (Co-PI w/ FH Epstein)

    Period: 07/01/13 – 05/31/17. Amount: $2,047,894 (Total direct & indirect over entire period)

  • A Bioengineering Approach to Gene Therapy for Peripheral Arterial Disease

    Source: NIH-NHLBI: R01 HL116455 (Multi-PI w/ BH Annex)

    Period: 04/01/2014 - 03/31/2018. Amount: $2,749,737 (Total direct & indirect over entire period)

  • Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer

    Source: NIH-NCI: R01 CA168712 (MPI w/ KA Kelly & C Logsdon)

    Period: 09/08/2014 – 08/31/2018. Amount: $1,972,724 (Total direct & indirect over entire period)